RAPT
RAPT Therapeutics, Inc.
Biotechnology
Market Cap$296M
5Y Perf.-60.3%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
RAPT vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.83B
5Y Perf.+8.1%
RAPT vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RAPT | IMVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $296M | $5.83B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-106M | $-464M |
| Total Debt | $4M | $98K |
| Cash & Equiv. | $170M | $714M |
RAPT vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RAPT
IMVT
| Stock | May 20 | Mar 26 | Return |
|---|---|---|---|
| RAPT Therapeutics, … (RAPT) | 100 | 39.7 | -60.3% |
| Immunovant, Inc. (IMVT) | 100 | 108.1 | +8.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RAPT vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RAPT leads in 3 of 5 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Immunovant, Inc. is the stronger pick specifically for operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
RAPT
RAPT Therapeutics, Inc.
The Income Pick
RAPT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.60
- EPS growth -4.6%
- Lower volatility, beta 0.60, Low D/E 2.4%, current ratio 4.87x
Best for: income & stability and growth exposure
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the clearest fit if your priority is long-term compounding.
- 188.1% 10Y total return vs RAPT's -44.2%
- -44.1% ROA vs RAPT's -54.7%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RAPT | 1.5% revenue growth vs IMVT's -21.3% |
| Stability / Safety | RAPT | Beta 0.60 vs IMVT's 1.37 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RAPT | +7.9% vs IMVT's +107.2% |
| Efficiency (ROA) | IMVT | -44.1% ROA vs RAPT's -54.7% |
RAPT vs IMVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRAPTLAGGINGIMVT
IMVTImmunovant, Inc.
2leads
RAPTRAPT Therapeutics, In…
2leads
6 Total Categories
CATEGORYLEADERvs IMVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RAPT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IMVT6/6
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT4/6
Risk & VolatilityBeta, volatility, and downside exposure
RAPT2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RAPT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
RAPT and IMVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | RAPTRAPT Therapeutics… | IMVTImmunovant, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$112M | -$487M |
| Net IncomeAfter-tax profit | -$106M | -$464M |
| Free Cash FlowCash after capex | -$87M | -$423M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +82.9% | +19.7% |
RAPT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — RAPT and IMVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | RAPTRAPT Therapeutics… | IMVTImmunovant, Inc. |
|---|---|---|
| Market CapShares × price | $296M | $5.8B |
| Enterprise ValueMkt cap + debt − cash | $130M | $5.1B |
| Trailing P/EPrice ÷ TTM EPS | -2.28x | -10.50x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 1.56x | 6.14x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — RAPT and IMVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
IMVT leads this category, winning 6 of 6 comparable metrics.
Profitability & Efficiency
IMVT delivers a -47.1% return on equity — every $100 of shareholder capital generates $-47 in annual profit, vs $-62 for RAPT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to RAPT's 0.02x.
| Metric | RAPTRAPT Therapeutics… | IMVTImmunovant, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -61.8% | -47.1% |
| ROA (TTM)Return on assets | -54.7% | -44.1% |
| ROICReturn on invested capital | -155.7% | — |
| ROCEReturn on capital employed | -79.3% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | 0.02x | 0.00x |
| Net DebtTotal debt minus cash | -$165M | -$714M |
| Cash & Equiv.Liquid assets | $170M | $714M |
| Total DebtShort + long-term debt | $4M | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
IMVT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $17,386 today (with dividends reinvested), compared to $3,463 for RAPT. Over the past 12 months, RAPT leads with a +792.4% total return vs IMVT's +107.2%. The 3-year compound annual growth rate (CAGR) favors IMVT at 14.1% vs RAPT's -27.4% — a key indicator of consistent wealth creation.
| Metric | RAPTRAPT Therapeutics… | IMVTImmunovant, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | +82.1% | +10.7% |
| 1-Year ReturnPast 12 months | +792.4% | +107.2% |
| 3-Year ReturnCumulative with dividends | -61.7% | +48.4% |
| 5-Year ReturnCumulative with dividends | -65.4% | +73.9% |
| 10-Year ReturnCumulative with dividends | -44.2% | +188.1% |
| CAGR (3Y)Annualised 3-year return | -27.4% | +14.1% |
IMVT leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
RAPT leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
RAPT is the less volatile stock with a 0.60 beta — it tends to amplify market swings less than IMVT's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RAPT currently trades 100.0% from its 52-week high vs IMVT's 95.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RAPTRAPT Therapeutics… | IMVTImmunovant, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.60x | 1.37x |
| 52-Week HighHighest price in past year | $58.02 | $30.09 |
| 52-Week LowLowest price in past year | $5.67 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +100.0% | +95.3% |
| RSI (14)Momentum oscillator 0–100 | 78.9 | 55.7 |
| Avg Volume (50D)Average daily shares traded | 6.9M | 1.4M |
RAPT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates RAPT as "Hold" and IMVT as "Buy". Consensus price targets imply 58.7% upside for IMVT (target: $46) vs -0.0% for RAPT (target: $58).
| Metric | RAPTRAPT Therapeutics… | IMVTImmunovant, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $58.00 | $45.50 |
| # AnalystsCovering analysts | 15 | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RAPT leads in 2 of 6 categories (Income & Cash Flow, Risk & Volatility). IMVT leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Best OverallRAPT Therapeutics, Inc. (RAPT)Leads 2 of 6 categories
Loading custom metrics...
RAPT vs IMVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is RAPT or IMVT a better buy right now?
Analysts rate Immunovant, Inc.
(IMVT) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RAPT or IMVT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +73. 9%, compared to -65. 4% for RAPT Therapeutics, Inc. (RAPT). Over 10 years, the gap is even starker: IMVT returned +188. 1% versus RAPT's -44. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RAPT or IMVT?
By beta (market sensitivity over 5 years), RAPT Therapeutics, Inc.
(RAPT) is the lower-risk stock at 0. 60β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 129% more volatile than RAPT relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 2% for RAPT Therapeutics, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — RAPT or IMVT?
On earnings-per-share growth, the picture is similar: RAPT Therapeutics, Inc.
grew EPS -4. 6% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — RAPT or IMVT?
RAPT Therapeutics, Inc.
(RAPT) is the more profitable company, earning 0. 0% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RAPT leads at 0. 0% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — RAPT leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — RAPT or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is RAPT or IMVT better for a retirement portfolio?
For long-horizon retirement investors, RAPT Therapeutics, Inc.
(RAPT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 60)). Both have compounded well over 10 years (RAPT: -44. 2%, IMVT: +188. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between RAPT and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.